How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Oracle’s fourth-quarter earnings call will deliver critical updates about the progress of its data-center build-out and the financial impact of its AI pivot.

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

One of the world’s leading artificial intelligence companies has implored the industry to pause development on AI, because the latest models could be reaching a tipping point where they become capable ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Oracle shed 13% of its workforce while spending $55.7 billion on data centres. Its SEC filing explicitly cites AI adoption as the cause of job losses.

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

This week’s cybersecurity recap covers Firefox and Chrome bugs, EDR-killer tools, a TV botnet, an OpenBSD flaw, Android ...

The job cuts made headlines. But the bigger story is what's funding them.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.